{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:55:42Z","timestamp":1792785342527,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Royal Marsden NIHR Biomedical Research Centre"},{"name":"National Institute for Health Research Academic Clinical Fellowship","id":[{"id":"https:\/\/ror.org\/0187kwz08","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.clon.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T13:31:18Z","timestamp":1456666278000},"page":"597-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"H.","family":"Lote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Redana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Papadimitraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Capelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2016.02.003_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2010.32.1752","article-title":"Obesity and breast cancer prognosis: weight of the evidence","volume":"29","author":"Sinicrope","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.02.003_bib2","unstructured":"Centre Hasci. Statistics on obesity, physical activity and diet \u2013 England. Available at: http:\/\/www.hscic.gov.uk\/catalogue\/PUB136482014."},{"key":"10.1016\/j.clon.2016.02.003_bib3","unstructured":"Cancer Research UK. Body weight and cancer: the evidence 2015. Available at: http:\/\/www.cancerresearchuk.org\/cancer-info\/healthyliving\/obesity-bodyweight-and-cancer\/stats-evidence\/."},{"issue":"1","key":"10.1016\/j.clon.2016.02.003_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/mdu509","article-title":"Obesity and the outcome of young breast cancer patients in the UK: the POSH study","volume":"26","author":"Copson","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clon.2016.02.003_bib5","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer \u2013 systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clon.2016.02.003_bib6","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2016.02.003_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.clon.2016.02.003_bib8","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2016.02.003_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3747\/co.v18i3.751","article-title":"Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres","volume":"18","author":"Madarnas","year":"2011","journal-title":"Curr Oncol"},{"issue":"36","key":"10.1016\/j.clon.2016.02.003_bib10","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roche","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2016.02.003_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clon.2016.02.003_bib12","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3747\/co.19.940","article-title":"Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study","volume":"19","author":"Rayson","year":"2012","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.clon.2016.02.003_bib13","first-page":"2523","article-title":"Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis","volume":"20","author":"Younis","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.clon.2016.02.003_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12032-014-0881-z","article-title":"Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women","volume":"31","author":"Carroll","year":"2014","journal-title":"Med Oncol"},{"issue":"10","key":"10.1016\/j.clon.2016.02.003_bib15","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/annonc\/mdt224","article-title":"Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients","volume":"24","author":"Jiralerspong","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clon.2016.02.003_bib16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archinte.165.11.1267","article-title":"Undertreatment of obese women receiving breast cancer chemotherapy","volume":"165","author":"Griggs","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.clon.2016.02.003_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","article-title":"Effect of obesity on prognosis after early-stage breast cancer","volume":"29","author":"Ewertz","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2016.02.003_bib18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejca.2013.11.013","article-title":"Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials","volume":"50","author":"Ladoire","year":"2014","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clon.2016.02.003_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-012-2213-3","article-title":"Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review","volume":"136","author":"Carroll","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.clon.2016.02.003_bib20","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/annonc\/mdt294","article-title":"Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis","volume":"24","author":"Hourdequin","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clon.2016.02.003_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/clpt.2014.136","article-title":"Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation","volume":"96","author":"Lashinger","year":"2014","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:42:55Z","timestamp":1760542975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655516000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0936655516000807"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2016.02.003","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}